GERON CORP Increase (Decrease) in Prepaid Expense and Other Assets
GERON CORP (GERN) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- GERON CORP increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$974.00K.
- GERON CORP increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.23M, a 32.35% increase year-over-year.
- GERON CORP increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.34M, a 351.41% decline year-over-year.
- GERON CORP increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was -$515.00K, a 205.10% decline year-over-year.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month |
|---|---|---|---|
| 2026-06-30 | -$974.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.26M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $2.23M 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.85M derived: sum of 2 quarters · filed 2026-08-05 | -$167.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$515.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.17M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $1.69M 10-Q · filed 2026-05-06 | ||
| 2024-09-30 | $533.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.02M derived: sum of 2 quarters · filed 2025-11-07 | $1.84M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $490.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.31M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $819.00K 10-Q · filed 2025-05-07 | ||
| 2023-09-30 | $16.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $13.69M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$2.41M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |